Glucagon-like peptide 1 improved glycemic control in type 1 diabetes

BACKGROUND: Glucagon-like peptide-1 (GLP-1) and its agonists are under assessment in treatment of type 2 diabetes, by virtue of their antidiabetic actions, which include stimulation of insulin secretion, inhibition of glucagon release, and delay of gastric emptying. We examined the potential of GLP-...

Descripción completa

Detalles Bibliográficos
Autores principales: Behme, Margaret T, Dupré, John, McDonald, Thomas J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC154101/
https://www.ncbi.nlm.nih.gov/pubmed/12697069
http://dx.doi.org/10.1186/1472-6823-3-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC154101/
https://www.ncbi.nlm.nih.gov/pubmed/12697069
http://dx.doi.org/10.1186/1472-6823-3-3

Ejemplares similares